Beam director granted options on 19,676 shares
Beam Therapeutics Inc. director Mark Fishman received a grant of stock options covering 19,676 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Beam Therapeutics Inc. director Mark Fishman received a grant of stock options covering 19,676 shares of common stock. The options have an exercise price of $29.55 per share and were awarded as compensation, not purchased in the open market.
The option vests in full on the earlier of the first anniversary of the grant date or immediately before next year’s annual stockholder meeting, as long as Fishman continues serving on the board through that date. The options expire on June 3, 2036, giving him long-term potential ownership if exercised.
Insider Trade Summary
Grant/Award: 19,676 shares
Grant/Award
1 txn
Insider
Fishman Mark
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 19,676 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 19,676 contracts (Direct)
Footnotes (1)
- F1. The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.
Key Figures
Options granted: 19,676 options
Exercise price: $29.55 per share
Underlying shares: 19,676 shares
+3 more
6 metrics
Options granted
19,676 options
Stock Option (Right to Buy) grant to director
Exercise price
$29.55 per share
Conversion/exercise price of granted options
Underlying shares
19,676 shares
Common stock underlying the option grant
Expiration date
June 3, 2036
Option term end date
Shares after transaction
19,676 options
Total derivative holdings following grant
Transaction date
June 3, 2026
Date of option grant
Key Terms
Stock Option (Right to Buy), exercise price, underlying security, expiration date, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "29.5500" per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
underlying security financial
"underlying_security_title: "Common Stock""
expiration date financial
"expiration_date: "2036-06-03T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vesting financial
"The option vests in full on the earlier of the first anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Beam Therapeutics (BEAM) director Mark Fishman report in this Form 4?
Mark Fishman reported receiving a compensatory stock option grant for 19,676 shares of Beam Therapeutics common stock. The award is a derivative security, giving him the right to buy shares later at a fixed exercise price of $29.55 per share.
Is the Beam Therapeutics (BEAM) Form 4 transaction a stock purchase or sale?
The Form 4 shows a stock option grant, not a share purchase or sale. Fishman acquired options at no cost, giving him the right to buy 19,676 Beam shares later at $29.55 per share if he chooses to exercise.
What are the key terms of Mark Fishman’s Beam Therapeutics (BEAM) option grant?
The grant covers 19,676 underlying Beam common shares at a $29.55 exercise price. The option vests fully on the earlier of one year from grant or just before the next annual shareholder meeting, and expires on June 3, 2036, if not exercised.
How does the Beam Therapeutics (BEAM) option granted to Mark Fishman vest?
The option vests in full once a time-based condition is met. Vesting occurs on the earlier of the first anniversary of the grant date or immediately before next year’s annual shareholder meeting, subject to his continued board service through that date.
How many Beam Therapeutics (BEAM) options does Mark Fishman hold after this filing?
Following this grant, the filing shows Fishman holding 19,676 stock options directly. Each option is exercisable into one share of Beam common stock at $29.55, providing potential equity exposure if he exercises in the future.
When do Mark Fishman’s Beam Therapeutics (BEAM) options expire?
The options are long-dated and expire on June 3, 2036, if not exercised. This extended term gives Fishman many years to decide whether to exercise, depending on his service on the board and Beam’s future share performance.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates